What is the clinical evidence from this study?

Study design: Review. Population: Diabetes mellitus and atrial fibrillation. Intervention: Diabetes mellitus and upstream therapies (thiazolidinediones, probucol, ACEI/ARBs).

What question did this study set out to answer?

To review the pathophysiological mechanisms linking diabetes mellitus to diabetic atrial remodeling and to summarize potential upstream therapies for atrial fibrillation prevention.

July 26, 2014Cardiovascular TherapeuticsOpen Access

Diabetes Mellitus and Atrial Remodeling: Mechanisms and Potential Upstream Therapies

View Full Paper

Ask AI

Bookmark

Key result

This review highlights the relationship between diabetes and atrial remodeling, suggesting upstream therapies like thiazolidinediones, probucol, and ACEI/ARBs may help prevent and treat atrial fibrillation.

Why the study?

What are the mechanisms of diabetes-related atrial remodeling and the potential role of upstream therapies in preventing atrial fibrillation?

Population

Patients with diabetes mellitus at risk of atrial fibrillation

Design

Review

Authors

QZQitong ZhangHarbin Institute of Technology TLTong LiuElectrophysiology CNChee Yuan NgMassachusetts General Hospital

Discussion

Member takes

Implication

Hypothesis-generating for upstream therapies targeting diabetic atrial remodeling; prospective RCTs needed before clinical adoption.

Key Points

To review the pathophysiological mechanisms linking diabetes mellitus to diabetic atrial remodeling and to summarize potential upstream therapies for atrial fibrillation prevention.
Synthesized evidence from experimental and clinical literature regarding diabetic atrial fibrillation.
Assessed pathological pathways underlying structural, electrical, and autonomic atrial remodeling, alongside potential pharmacological agents.
Established that diabetes mellitus elevates atrial fibrillation risk by driving coordinated structural, electrical, and autonomic atrial remodeling.
Identified upstream pharmacological therapies—including thiazolidinediones, probucol, and ACE inhibitors or angiotensin receptor blockers—as promising candidates to prevent or treat diabetic atrial remodeling.

Structured PICO

What are the mechanisms of diabetes-related atrial remodeling and the potential role of upstream therapies in preventing atrial fibrillation?

Population

Patients with diabetes mellitus at risk of atrial fibrillation

Exposure

Upstream therapies including thiazolidinediones, probucol, and ACEI/ARBs

Outcome

Atrial remodeling (structural, electrical, and autonomic) and atrial fibrillation

This review highlights the mechanisms linking diabetes to atrial remodeling and suggests that upstream therapies may help prevent atrial fibrillation in diabetic patients.

Cite This Study

Zhang et al. (2014) conducted a review in Diabetes mellitus and atrial fibrillation. Diabetes mellitus and upstream therapies (thiazolidinediones, probucol, ACEI/ARBs) was evaluated. This review highlights the relationship between diabetes and atrial remodeling, suggesting upstream therapies like thiazolidinediones, probucol, and ACEI/ARBs may help prevent and treat atrial fibrillation.

synapsesocial.com/papers/6a6f2e3bac440176ef27e528 https://doi.org/10.1111/1755-5922.12089

Topics

Atrial fibrillation Persistent AF management Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Diabetes Mellitus and Atrial Remodeling: Mechanisms and Potential Upstream Therapies

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Diabetes Mellitus and Atrial Remodeling: Mechanisms and Potential Upstream Therapies

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider